Secreted Frizzled-related protein 2 ( sFRP 2 ) as a target 2 in anti-fibrotic therapeutic intervention 3 4

Content Provider	Semantic Scholar
Author	Mastri, Michalis Shah, Zaeem Hsieh, Karin Wang, Xiaowen Wooldridge, Bailey Martin, S. C. Suzuki, Gen Lee, Techung
Copyright Year	2013
Abstract	22 23 24 Progressive fibrosis is a pathological hallmark of many chronic diseases responsible for 25 organ failure. Although there is currently no therapy on the market that specifically targets 26 fibrosis, the dynamic fibrogenic process is known to be regulated by multiple soluble mediators 27 that may be therapeutically intervened. The failing hamster heart exhibits marked fibrosis and 28 increased expression of secreted Frizzled-related protein 2 (sFRP2) amenable to reversal by 29 mesenchymal stem cell (MSC) therapy. Given the previous demonstration that sFRP2-null mice 30 subjected to myocardial infarction exhibited reduced fibrosis and improved function, we tested 31 whether antibody-based sFRP2 blockade might counteract the fibrogenic pathway and repair 32 cardiac injury. Cardiomyopathic hamsters were injected intraperitoneally twice a week each with 33 20 μg of sFRP2 antibody. Echocardiography, histology and biochemical analyses were 34 performed after one month. sFRP2 antibody increased left ventricular ejection fraction from 40 ± 35 1.2% to 49 ± 6.5%, whereas saline and IgG control exhibited a further decline to 37 ± 0.9% and 36 31 ± 3.2%, respectively. Functional improvement is associated with a ~50% reduction in 37 myocardial fibrosis, ~65% decrease in apoptosis and ~75% increase in wall thickness. 38 Consistent with attenuated fibrosis, both MSC therapy and sFRP2 antibody administration 39 significantly increased the activity of myocardial matrix metalloproteinase-2. Gene expression 40 analysis of the hamster heart and cultured fibroblasts identified Axin2 as a downstream target, 41 the expression of which was activated by sFRP2 but inhibited by therapeutic intervention. 42 sFRP2 blockade also increased myocardial levels of VEGF and HGF along with increased 43 angiogenesis. These findings highlight the pathogenic effect of dysregulated sFRP2, which may 44 be specifically targeted for anti-fibrotic therapy. 45 46 47
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://ajpcell.physiology.org/content/ajpcell/early/2013/12/06/ajpcell.00238.2013.full.pdf
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article